Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Radiopharm Theranostics Limited ( (AU:RAD) ) has issued an announcement.
Radiopharm Theranostics Limited has announced the quotation of 30,969,360 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective June 11, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operational capabilities and stakeholder interests positively.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is primarily involved in creating innovative solutions for cancer treatment and diagnosis, leveraging advanced technologies in the field of nuclear medicine.
Average Trading Volume: 4,325,527
Technical Sentiment Signal: Sell
Current Market Cap: A$56.02M
Find detailed analytics on RAD stock on TipRanks’ Stock Analysis page.